- Home
- EDIT vs CEE Comparison
EDIT vs CEE Comparison
Compare EDIT & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- CEE
- Stock Information
- Founded
- EDIT 2013
- CEE 1990
- Country
- EDIT United States
- CEE Germany
- Employees
- EDIT N/A
- CEE N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- CEE Finance Companies
- Sector
- EDIT Health Care
- CEE Finance
- Exchange
- EDIT Nasdaq
- CEE Nasdaq
- Market Cap
- EDIT 115.5M
- CEE 101.9M
- IPO Year
- EDIT 2016
- CEE N/A
- Fundamental
- Price
- EDIT $1.79
- CEE $15.20
- Analyst Decision
- EDIT Buy
- CEE
- Analyst Count
- EDIT 13
- CEE 0
- Target Price
- EDIT $6.73
- CEE N/A
- AVG Volume (30 Days)
- EDIT 1.9M
- CEE 22.0K
- Earning Date
- EDIT 05-12-2025
- CEE 01-01-0001
- Dividend Yield
- EDIT N/A
- CEE 3.86%
- EPS Growth
- EDIT N/A
- CEE N/A
- EPS
- EDIT N/A
- CEE N/A
- Revenue
- EDIT $35,837,000.00
- CEE N/A
- Revenue This Year
- EDIT N/A
- CEE N/A
- Revenue Next Year
- EDIT N/A
- CEE N/A
- P/E Ratio
- EDIT N/A
- CEE N/A
- Revenue Growth
- EDIT N/A
- CEE N/A
- 52 Week Low
- EDIT $0.91
- CEE $7.80
- 52 Week High
- EDIT $6.22
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- EDIT 60.00
- CEE 48.85
- Support Level
- EDIT $1.70
- CEE $15.20
- Resistance Level
- EDIT $1.95
- CEE $15.90
- Average True Range (ATR)
- EDIT 0.15
- CEE 0.55
- MACD
- EDIT 0.03
- CEE -0.08
- Stochastic Oscillator
- EDIT 76.03
- CEE 8.65
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.